Cepheid(NASDAQ:CPHD) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Jul 28, 2016. Company reported revenue of $146.00M. Analysts estimated a revenue of $145.94M. Earnings per share were $0.05.
In a different note, Morgan Stanley said it Initiates Coverage on Cepheid, according to a research note issued on Jun 15, 2016. The shares have been rated ‘Equal-weight’ by the firm.
Cepheid (CPHD) shares turned negative on Thursdays trading session with the shares closing down -0.15 points or -0.41% at a volume of 9,17,583. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $37.5. The peak price level was also seen at $37.5 while the days lowest was $36.54. Finally the shares closed at $36.65. The 52-week high of the shares is $56.36 while the 52-week low is $25.09. According to the latest information available, the market cap of the company is $2,671 M.
Several Insider Transactions has been reported to the SEC. On May 3, 2016, Scott A. Campbell (Corporate VP & CRO) sold 2,058 shares at $27.90 per share price.Also, On May 3, 2016, Peter V. Farrell (EVP, Worldwide Commercial Ops) sold 390 shares at $28.90 per share price.On Apr 27, 2016, John L Bishop (Chairman of the Board and CEO) sold 110,000 shares at $35.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Cepheid is a molecular diagnostics company. The Company develops manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps including sample preparation DNA amplification and detection. The Companys systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system which integrates sample preparation in addition to DNA amplification and detection serves reference laboratories and hospital central laboratories to satellite testing locations such as emergency departments and intensive care units within hospitals as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system which integrates DNA amplification and detection to allow rapid analysis of a sample.